Morphofunctional approach in the diagnosis of cardiac allograft vasculopathy: a case report
https://doi.org/10.15829/1728-8800-2024-4106
EDN: ZULNYD
Abstract
Cardiac allograft vasculopathy (CAV) remains an unsolved problem in modern transplantology. This pathological process leads to the death of 10% of heart recipients within 15 years. Early diagnosis of CAV improves the prognosis of transplanted heart patients. Coronary angiography has limitations in the assessment of intimal hyperplasia in CAV patients whereas intravascular imaging and coronary physiology assessment are essential aids in its early detection. The case of the using morphofunctional approach in CAV diagnosis is presented. To determine the functional significance of stenosis, fractional flow reserve was measured invasively. Optical coherence tomography allowed us to assess morphological substrate and confirm the autoimmune pathogenesis. Morphofunctional approach in this group of patients enables a more precise prediction of the disease's course and adequate treatment.
About the Authors
A. Yu. Kolesnikov
Research Institute for Complex Issues of Cardiovascular Diseases
Russian Federation
Russian Federation
Kemerovo
G. A. Teterin
Kemerovo State Medical University
Russian Federation
Russian Federation
Kemerovo
A. A. Arnt
Research Institute for Complex Issues of Cardiovascular Diseases
Russian Federation
Russian Federation
Kemerovo
N. A. Kochergin
Research Institute for Complex Issues of Cardiovascular Diseases
Russian Federation
Russian Federation
Kemerovo
References
1. Pighi M, Gratta A, Marin F, et al. Cardiac allograft vasculopathy: Pathogenesis, diagnosis and therapy. Transplant Rev (Orlando). 2020;34(4):100569. doi:10.1016/j.trre.2020.100569.
2. Mendiz OA, Gamboa P, Renedo MF, et al. Intravascular ultrasound for cardiac allograft vasculopathy detection. Clin Transplant. 2021;35(2):e14167. doi:10.1111/ctr.14167.
3. Khandhar SJ, Yamamoto H, Teuteberg JJ, et al. Optical coherence tomography for characterization of cardiac allograft vasculopathy after heart transplantation (OCTCAV study). J Heart Lung Transplant. 2013;32(6):596-602. doi:10.1016/j.healun.2013.02.005.
4. Hou J, Lv H, Jia H, et al. OCT assessment of allograft vasculopathy in heart transplant recipients. JACC Cardiovasc Imaging. 2012;5(6):662-3. doi:10.1016/j.jcmg.2012.01.018.
5. Sakhovsky SA, Koloskova NN, Goncharova AYu, et al. Intravascular visualization methods in estimating vasculopathy of a transplanted heart. Russian Journal of Transplantology and Artificial Organs. 2019;21(1):165-8. (In Russ.) doi:10.15825/1995-1191-2019-1-165-168.
6. Lee F, Nair V, Chih S. Cardiac allograft vasculopathy: Insights on pathogenesis and therapy. Clin Transplant. 2020;34(3):e13794. doi:10.1111/ctr.13794.
7. Velleca A, Shullo MA, Dhital K, et al. The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2023;42(5):e1-e141. doi:10.1016/j.healun.2022.10.015.
8. Pollack A, Nazif T, Mancini D, et al. Detection and imaging of cardiac allograft vasculopathy. JACC Cardiovasc Imaging. 2013;6(5):613-23. doi:10.1016/j.jcmg.2013.03.001.
9. Olymbios M, Kwiecinski J, Berman DS, et al. Imaging in Heart Transplant Patients. JACC Cardiovasc Imaging. 2018;11(10): 1514-30. doi:10.1016/j.jcmg.2018.06.019.
10. Clemmensen TS, Jensen NM, Eiskjær H. Imaging of Cardiac Transplantation: An Overview. Semin Nucl Med. 2021;51(4): 335-48. doi:10.1053/j.semnuclmed.2020.12.012.
11. Nagumo S, Gallinoro E, Candreva A, et al. Vessel Fractional Flow Reserve and Graft Vasculopathy in Heart Transplant Recipients. J Interv Cardiol. 2020;12;2020:9835151. doi:10.1155/2020/9835151.
12. Böhm F, Mogensen B, Östlund O, et al. The Full Revasc (FfrgUidance for compLete non-cuLprit REVASCularization) Registrybased randomized clinical trial. Am Heart J. 2021;241:92-100. doi:10.1016/j.ahj.2021.07.007.
13. Lee MS, Tadwalkar RV, Fearon WF, et al. Cardiac allograft vasculopathy: A review. Catheter Cardiovasc Interv. 2018;92(7): E527-36. doi:10.1002/ccd.27893.
14. Mileva N, Nagumo S, Gallinoro E, et al. Validation of Coronary Angiography-Derived Vessel Fractional Flow Reserve in Heart Transplant Patients with Suspected Graft Vasculopathy. Diagnostics (Basel). 2021;11(10):1750. doi:10.3390/diagnostics11101750.
15. Kal’chenko EA, Goncharova AYu, Sakhovsky SA. Problem of diagnosis and treatment of the cardiac allograft vasculopathy (literature review). J Diagnostic and Interventional Radiology. 2019;13(3):58-67. (In Russ.) doi:10.25212/DIR.2019.13.3.07.
16. Torres HJ, Merello L, Ramos SA, et al. Prevalence of cardiac allograft vasculopathy assessed with coronary angiography versus coronary vascular ultrasound and virtual histology. Transplant Proc. 2011;43(6):2318-21. doi:10.1016/j.transproceed.2011.06.002.
17. Kolesnikov AYu, Arnt AA, Kochergin NA. Capabilities of intravascular imaging techniques in the diagnosis of cardiac allograft vasculopathy: Literature review. Russian Journal of Transplantology and Artificial Organs. 2024;26(1):97-102. (In Russ.) doi:10.15825/1995-1191-2024-1-97-102.
Supplementary files
- Early diagnosis of cardiac allograft vasculopathy (CAV) using morphofunctional approach is presented.
- Estimation of both morphological substrate by optical coherence tomography and functional significance of stenosis by fractional flow reserve method allows to diagnose CAV with greater reliability at early stages.
- The morphofunctional approach in CAV assessment allows predicting the disease course and determining the adequate therapy.
Review
For citations:
Kolesnikov A.Yu., Teterin G.A., Arnt A.A., Kochergin N.A. Morphofunctional approach in the diagnosis of cardiac allograft vasculopathy: a case report. Cardiovascular Therapy and Prevention. 2024;23(12):4106. (In Russ.) https://doi.org/10.15829/1728-8800-2024-4106. EDN: ZULNYD
Views:
125
Email this article 
